Research advances in immunotherapy for hepatocellular carcinoma

ZHU Lizhen,XU Xiaolei,ABUDUSALAMU Aini,WANG Xiaojuan,ZHOU Hu,TANG Rui,FAN Haining,LU Qian

DOI: https://doi.org/10.3969/j.issn.1001-5256.2023.05.031

2023-01-01

Abstract:Hepatocellular carcinoma（HCC） has an insidious onset, and most patients are in the advanced stage when attending the hospital and thus lose the opportunity for radical surgical resection, which results in the poor prognosis of patients. With the development of clinical treatment, the treatment of advanced HCC has gradually transitioned from the relatively single and limited treatment options in the past to the new model of comprehensive treatment. In recent years, immunotherapy, represented by immune checkpoint inhibitors（ICIs）, has become widely used in clinical practice. At present, a number of clinical studies have been conducted for immunotherapy combined with local and targeted antitumor therapy, and in particular, ICIs combined with targeted therapy have become a research hotspot in the field of HCC treatment. This article reviews the research advances in immunotherapy for the treatment of HCC.